Macrolide-resistant Streptococcus pyogenes in the United states, 2002-2003

被引:97
|
作者
Richter, SS
Heilmann, KP
Beekmann, SE
Miller, NJ
Miller, AL
Rice, CL
Doern, CD
Reid, SD
Doern, GV
机构
[1] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27103 USA
关键词
D O I
10.1086/432473
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Increased levels of macrolide-resistant Streptococcus pyogenes in focal regions of the United States have been reported. The purpose of this study was to determine the antimicrobial susceptibility of a large collection of S. pyogenes isolates from throughout the United States and to elucidate the mechanisms of resistance and genetic relatedness of macrolide-resistant isolates. Methods. During 2002-2003, a total of 1885 S. pyogenes clinical isolates were obtained from 45 US medical centers. Susceptibility to penicillin, cefdinir, erythromycin, azithromycin, clarithromycin, clindamycin, telithromycin, and levofloxacin was determined. Macrolide resistance phenotypes were determined by double-disk diffusion, and macrolide resistance genotypes were determined by polymerase chain reaction and sequencing. All macrolide-resistant isolates and all isolates recovered from sterile sites were further characterized by pulsed-field gel electrophoresis (PFGE) and emm typing. Results. The majority (85%) of isolates were pharyngeal. Resistance was detected to erythromycin (6.8% of isolates), azithromycin (6.9%), clarithromycin (6.6%), clindamycin (0.5%), telithromycin (0.2%), and levofloxacin (0.05%). The macrolide-resistance phenotype distribution was as follows: macrolide-lincosamide-streptogramin B (MLSB), 56% of isolates (inducible, 47%; constitutive, 9%); and M, 44%. The genotypes detected were as follows: ermA, 46% of isolates (95% with inducible MLSB phenotype); mefA, 43% (all with M phenotype); and ermB, 8.5% (45% with inducible MLSB and 45% with constitutive MLSB). Three isolates with constitutive MLSB phenotypes had 23S ribosomal RNA mutations. The 129 erythromycin-resistant isolates belonged to 28 emm types and 44 PFGE patterns, with 51% of the isolates in 4 major PFGE clones each associated with a predominant emm type (emm75, emm58, emm12, and emm114) and resistance genotype (mefA or ermA)). Conclusions. The population of macrolide-resistant S. pyogenes isolates in the United States is small, but it includes several large clones with potential for expansion.
引用
收藏
页码:599 / 608
页数:10
相关论文
共 50 条
  • [31] Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents
    Pihlajamäki, M
    Kotilainen, P
    Kaurila, T
    Klaukka, T
    Palva, E
    Huovinen, P
    Kostiala-Thompson, A
    Renkonen, R
    Muotiala, A
    Vaara, M
    Sivonen, A
    Jousimies-Somer, H
    Laitinen, K
    Korpela, J
    Kaukoranta-Tolvanen, SS
    Hiekkaniemi, H
    Hirvonen, P
    Nissinen, A
    Ruuska, P
    Ahonen, E
    Jägerroos, H
    Räisänen, S
    Larinkari, U
    Forsblom, B
    Katila, ML
    Färkkäinen, U
    Sarkkinen, H
    Kärpänoja, P
    Kauppinen, M
    Paltemaa, S
    Kärkkäinen, P
    Silvennoinen-Kassinen, S
    Lantto, K
    Koskela, M
    Pietarinen, I
    Klossner, ML
    Pajarre, S
    Oinonen, S
    Ratia, V
    Grönroos, P
    Vuento, R
    Liimatainen, O
    Siro, MR
    Eerola, E
    Maninen, R
    Meurman, O
    Luukkonen, S
    Strandén, P
    Lager, K
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (04) : 483 - 488
  • [32] Correlation of serotypes and genotypes of macrolide-resistant Streptococcus agalactiae
    Uh, Y
    Kim, HY
    Jang, IH
    Hwang, GY
    Yoon, KJ
    [J]. YONSEI MEDICAL JOURNAL, 2005, 46 (04) : 480 - 483
  • [33] Faculty and finances of United States anesthesiology training programs: 2002-2003
    Tremper, KK
    Shanks, A
    Sliwinski, M
    Barker, SJ
    Hines, R
    Tait, AR
    [J]. ANESTHESIA AND ANALGESIA, 2004, 99 (04): : 1185 - 1192
  • [34] Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe
    Reinert, RR
    Ringelstein, A
    van der Linden, M
    Cil, MY
    Al-Lahham, A
    Schmitz, FJ
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (03) : 1294 - 1300
  • [35] Macrolides Decrease the Proinflammatory Activity of Macrolide-Resistant Streptococcus pneumoniae
    Domon, Hisanori
    Hirayama, Satoru
    Isono, Toshihito
    Sasagawa, Karin
    Takizawa, Fumio
    Maekawa, Tomoki
    Yanagihara, Katsunori
    Terao, Yutaka
    [J]. MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [36] Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae
    Moellering, RC
    [J]. JOURNAL OF CHEMOTHERAPY, 2002, 14 : 42 - 56
  • [37] MACROLIDE-RESISTANT PHENOTYPES OF INVASIVE STREPTOCOCCUS PNEUMONIAE ISOLATES IN SERBIA
    Gajic, Ina
    Opavski, Natasa
    Mijac, Vera
    Ranin, L.
    [J]. ARCHIVES OF BIOLOGICAL SCIENCES, 2012, 64 (04) : 1377 - 1382
  • [38] A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae
    Rzeszutek, M
    Wierzbowski, A
    Hoban, DJ
    Conly, J
    Bishai, W
    Zhanel, GG
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (02) : 95 - 104
  • [39] Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program
    Waites, K. B.
    Ratliff, A.
    Crabb, D. M.
    Xiao, L.
    Qin, X.
    Selvarangan, R.
    Tang, Y-W
    Zheng, X.
    Bard, J. Dien
    Hong, T.
    Prichard, M.
    Brooks, E.
    Dallas, S.
    Duffy, L.
    Mixon, E.
    Fowler, K. B.
    Atkinson, T. P.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (11)
  • [40] Surveillance of invasive Streptococcus pneumoniae in Taiwan, 2002-2003
    Chen, Ying-Yan
    Yao, Shu-Man
    Chou, Chen-Ying
    Chang, Yi-Ching
    Shen, Pei-Wun
    Huang, Chung-Ter
    Su, Hsun-Pi
    Li, Shu-Ying
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (08) : 1109 - 1114